Kelleher Financial Advisors increased its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 50.4% during the second quarter, HoldingsChannel reports. The firm owned 17,508 shares of the company’s stock after acquiring an additional 5,868 shares during the period. Kelleher Financial Advisors’ holdings in AbbVie were worth $4,406,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ABBV. Litman Gregory Wealth Management LLC purchased a new stake in shares of AbbVie in the fourth quarter worth about $28,000. Imprint Wealth LLC lifted its stake in AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after purchasing an additional 45 shares in the last quarter. IFC & Insurance Marketing Inc. purchased a new stake in AbbVie in the 4th quarter worth approximately $31,000. Legacy Wealth Managment LLC ID boosted its holdings in AbbVie by 115.9% in the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after purchasing an additional 73 shares during the period. Finally, Marquette Asset Management LLC boosted its holdings in AbbVie by 52.2% in the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock valued at $35,000 after purchasing an additional 48 shares during the period. 70.23% of the stock is currently owned by institutional investors.
More AbbVie News
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: AbbVie’s Humira replacement strategy is gaining credibility: second-quarter revenue rose 10.2% to $16.99 billion, led by immunology products and supported by neuroscience. This suggests Skyrizi, Rinvoq and other newer medicines are more than offsetting Humira’s biosimilar-related decline. AbbVie’s Humira Replacement Strategy Is Working
- Positive Sentiment: New lung-cancer data for investigational treatments ABBV-1480, ABBV-706 and Temab-A point to potentially meaningful future growth in oncology. Reported response rates and manageable safety profiles strengthen the case for AbbVie’s longer-term pipeline, though the programs remain dependent on additional clinical results and approvals. Is AbbVie Quietly Rebalancing Its Growth Story Around Oncology Innovation?
- Positive Sentiment: Several investment managers increased their AbbVie holdings, including Convergence Financial, which nearly doubled its position, and Donaldson Capital Management, which modestly raised its stake. These filings provide a supportive institutional signal but are not major earnings catalysts. Convergence Financial Increased Its AbbVie Holdings
- Neutral Sentiment: In comparisons with Eli Lilly, AbbVie offers a more established cash-generating portfolio and attractive pipeline opportunities, while Lilly has stronger headline growth prospects. The debate highlights AbbVie’s balance between income, stability and pipeline execution rather than a clear near-term catalyst. LLY vs. ABBV: Which Stock Has the Stronger Growth Prospects?
- Negative Sentiment: Second-quarter oncology sales declined 2.4% as Imbruvica continued to weaken. Growth from Venclexta and newer medicines partly offset the pressure, but the result underscores ongoing reliance on successful launches and pipeline products to revive the franchise. How Did AbbVie’s Oncology Sales Hold Up in Q2?
Insiders Place Their Bets
Analyst Ratings Changes
Several research analysts have recently weighed in on ABBV shares. Bank of America upped their price target on shares of AbbVie from $234.00 to $276.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Wolfe Research upgraded AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 target price for the company in a research report on Thursday, August 13th. Royal Bank Of Canada upped their target price on AbbVie from $260.00 to $280.00 and gave the stock an “outperform” rating in a research note on Friday, July 10th. Canaccord Genuity Group raised their price target on AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Finally, JPMorgan Chase & Co. lifted their price target on AbbVie from $260.00 to $280.00 and gave the company an “overweight” rating in a research report on Thursday, July 9th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and an average price target of $275.95.
Get Our Latest Analysis on ABBV
AbbVie Stock Performance
ABBV stock opened at $265.56 on Wednesday. The company has a market capitalization of $469.18 billion, a PE ratio of 75.02, a price-to-earnings-growth ratio of 0.88 and a beta of 0.30. AbbVie Inc. has a one year low of $190.75 and a one year high of $267.47. The company’s 50 day moving average price is $250.20 and its two-hundred day moving average price is $228.12.
AbbVie (NYSE:ABBV – Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. During the same quarter in the prior year, the company earned $2.97 EPS. The firm’s revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, research analysts predict that AbbVie Inc. will post 14.06 EPS for the current year.
AbbVie Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were issued a dividend of $1.73 per share. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.6%. AbbVie’s dividend payout ratio is currently 195.48%.
AbbVie Profile
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Read More
- Five stocks we like better than AbbVie
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
